ReviewJACC. CardioOncology2021
BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab.
Review in JACC. CardioOncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients.BMC cancer · 2025Pooled it
- Effect of Cardioprotection on the Right Ventricular Function in Breast Cancer Patients Receiving Potentially Cardiotoxic Therapy: A SAFE Trial Substudy.Echocardiography (Mount Kisco, N.Y.) · 2025Trial
- Echocardiography in cardio-oncology: optimising service delivery.Echo research and practice · 2026Review
- Zebrafish Model Reveals Early Electrocardiographic and Molecular Signatures of Doxorubicin-Induced Cardiotoxicity.Cardiovascular toxicology · 2026Article
- The impact of heart rate on echocardiographic measures of left ventricular function: novel insights facilitated by deep learning.European heart journal. Imaging methods and practice · 2026Article
- CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis.Cardio-oncology (London, England) · 2025Article
- Cancer in pregnancy: FIGO Best practice advice and narrative review.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Review
- Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction.Cardio-oncology (London, England) · 2025Article
- Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment.Nature reviews. Cardiology · 2025Review
- How to Perform Cardiac Contrast-Enhanced Ultrasound (cCEUS): Part I.Diagnostics (Basel, Switzerland) · 2025Review
- 3D Echocardiographic Phenotyping of Left Ventricular Mechanics and Function With Contemporary Radiation Therapy.Advances in radiation oncology · 2025Article
- Cardio-Oncology and Multi-Imaging Modalities.Journal of clinical medicine · 2025Review
- Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy.JACC. CardioOncology · 2025Article
- Chinese guideline for the clinical application of noninvasive imaging technology in accessing cancer therapy-related cardiovascular toxicity.Journal of geriatric cardiology : JGC · 2025Article
- Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy.JACC. CardioOncology · 2025Article
- Genetic Background in Patients with Cancer Therapy-Induced Cardiomyopathy.Journal of clinical medicine · 2025Review
- Review
- SGLT2 inhibitors for prevention and management of cancer treatment-related cardiovascular toxicity: a review of potential mechanisms and clinical insights.Cardio-oncology (London, England) · 2025Review
- Accuracy of mitral annular plane systolic excursion in diagnosing anthracycline-induced subclinical cardiotoxicity in patients with breast cancer - a retrospective cohort study.Cardio-oncology (London, England) · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 18 institutions in 3 countries.
Funding
Abstract
The subspecialty of cardio-oncology aims to reduce cardiovascular morbidity and mortality in patients with cancer or following cancer treatment. Cancer therapy can lead to a variety of cardiovascular complications, including left ventricular systolic dysfunction, pericardial disease, and valvular heart disease. Echocardiography is a key diagnostic imaging tool in the diagnosis and surveillance for many of these complications. The baseline assessment and subsequent surveillance of patients undergoing treatment with anthracyclines and/or human epidermal growth factor receptor (HER) 2-positive targeted treatment (e.g., trastuzumab and pertuzumab) form a significant proportion of cardio-oncology patients undergoing echocardiography. This guideline from the British Society of Echocardiography and British Cardio-Oncology Society outlines a protocol for baseline and surveillance echocardiography of patients undergoing treatment with anthracyclines and/or trastuzumab. The methodology for acquisition of images and the advantages and disadvantages of techniques are discussed. Echocardiographic definitions for considering cancer therapeutics-related cardiac dysfunction are also presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.